Clinical Prognosis of Right-Sided Infective Endocarditis not Associated with Cardiac Devices or Intravenous Drug use: a Cohort Study and Meta-Analysis

Pau Vilardell Rigau 1, Sergio Moral 1✉, Daniel Bosch 1, Manel Morales 1, Josep Maria Frigola 1, Xavier Albert 1, Rocio Robles 1, Esther Ballesteros 1, Marta Roqué 1, Jaime Aboal 1 & Ramon Brugada 1

Right-sided infective endocarditis (RSIE), classically associated with intravenous drug use or intracardiac devices, is considered a good-prognosis infective endocarditis (IE) form. However, predisposing factors and prognosis for “NODID” RSIE (Not associated with cardiac Devices or Intravenous Drug use) remain unclear. The aim of this study was to evaluate predisposing factors and prognosis of NODID RSIE compared to other RSIE forms. A retrospective cohort study (January 2008–January 2019) was conducted in a reference center on 300 patients diagnosed with IE. Endocarditis-related events were defined as related to IE in mortality or open-heart surgery during follow-up. A review and meta-analysis of associated literature (January 2008-January 2019) were also performed. Fifty-seven patients presented RSIE (19%), 22 of which were NODID RSIE (39%). Use of intravascular catheters (23% vs 3%; \( p = 0.027 \)) and congenital heart diseases (18% vs 0%; \( p = 0.019 \)) were associated with NODID RSIE. This group had a higher in-hospital mortality (23% vs 3%; \( p = 0.027 \)) and endocarditis-related event rates (41% vs 6%; \( p = 0.001 \)) than non-NODID RSIE. Furthermore, NODID RSIE was independently associated with in-hospital endocarditis-related events (OR = 19.29; 95%CI:2.23–167.16; \( p = 0.007 \)). Our meta-analysis evaluated four studies and identified 96 cases (30%) of NODID RSIE from 320 total RSIE cases. NODID RSIE patients demonstrated higher in-hospital mortality (RR = 2.81; 95%CI:1.61–4.90; \( p < 0.001 \); \( I^2 = 0.0\% \)) and necessity of open-heart surgery (RR = 13.89; 95%CI:4.14–46.60; \( p < 0.001 \); \( I^2 = 0.0\% \)) than non-NODID RSIE cases. Our study suggests that NODID RSIE has the highest endocarditis-related event rate and in-hospital mortality among RSIE cases and therefore should not be considered a good-prognosis IE.

Right-sided infective endocarditis (RSIE) is considered a good-prognosis form of infective endocarditis (IE), with in-hospital mortality of 5–10%.1–4 This pathology is classically associated with intravenous drug use (IVDU) or intracardiac devices (pacemakers or defibrillators). Recommended treatment is antimicrobial therapy and complete hardware removal in cases associated with intracardiac devices, but rarely open-heart surgery1,5,6. The benign in-hospital course of RSIE is mainly based on youth and low comorbidities of IVDU cases and good results from combined antimicrobial treatment and hardware removal in patients with cardiac devices7–10. Nevertheless, in the past decade a new group of RSIE not associated with cardiac devices or IVDU (NODID) has been described, but its prognosis and predisposing factors are not well-established11–14. Some authors have indicated that these patients may have a worse disease course, raising the question of a potential need for new treatment approaches.15,16
therapeutic approaches in these cases\textsuperscript{11}. However, there is currently no consensus on the prognosis and best treatment option for NODID RSIE.

Therefore, this study determined the clinical evolution of NODID RSIE in a recent cohort of IE patients and established the possible predisposing factors for this group. Further, we conducted a systematic review and meta-analysis of recently published studies to evaluate the global prognosis of NODID RSIE.

Methods

Study population. From January 2008–January 2019, 300 consecutive patients diagnosed with IE were retrospectively included in this study. Of these 300 patients, 57 were diagnosed with RSIE (Fig. 1) according to modified Duke criteria\textsuperscript{1,15}. Patients were excluded if they had concomitant left-sided infective endocarditis (LSIE) or an unclear diagnosis. All patients underwent transthoracic echocardiography and transesophageal echocardiography and/or positron emission tomography–computed tomography if required. NODID RSIE was defined as RSIE patients without intracardiac devices or IVDU history. Those patients which we could not confirm this data were excluded. The protocol received institutional review board approval by University Doctor Josep Trueta hospital ethics committee. The informed consent was waived due to the retrospective nature of the study according to the ethics committee approval and all tests were performed in accordance with relevant guidelines and regulations.

Baseline measures and follow-up. Baseline clinical, microbiology, imaging, and medical and invasive treatment data were obtained from medical records. Medical and surgical treatment was determined by the endocarditis team of the institution, per guidelines and each case\textsuperscript{1,2}. Endocarditis-related events were defined as related to IE in mortality or open-heart surgery. Removal of cardiac devices was not considered open-heart surgery. Pulmonary and systemic embolisms were also collected. Malnourished patients were defined using the Mini Nutritional Assessment Short Form (MNA-SF)\textsuperscript{16}.

After discharge, retrospective follow-up was performed by medical record review or telephone contact. Causes of death were defined according to medical records and death certificates. Follow-up time was defined as number of months between the event and first endpoint event; the most recent outpatient visit or telephone contact was considered the end of follow-up for patients who did not reach an endpoint.

Systematic review and meta-analysis. Studies reported during January 2008–January 2019 that included RSIE were identified with EMBASE, MEDLINE, and PsycINFO searches (independently performed by P.V., S.M., and E.B.) by screening references of identified articles and by correspondence with study researchers using the approach recommended by Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Fig. 2)\textsuperscript{17}. Computer-based searches combined terms related to RSIE and right heart cavities with different synonyms in the medical literature (full details of the search strategy are provided in Supplementary Table A1). Studies were included if they had a cohort design, reported data on the prognosis of NODID and non-NODID RSIE cases and were published in peer-reviewed journals. NODID RSIE cases were defined as those...
without association to IVDU or cardiac devices. Studies without clear definition of NODIDRSIE or with < 15 patients were excluded. Case-control studies were also excluded.

Data extraction and quality assessment were conducted independently by two investigators (P.V. and S.M.), and all discrepancies were resolved by discussion and adjudication of a third reviewer (E.B.). The following data were extracted using a standardized form: study design, geographic location, sample size, average age of participants, percentage of male participants, number of cases with RSIE, number of patients with NODID and non-NODID RSIE at diagnosis, endocarditis mortality, and open-heart surgery related to IE.

The Newcastle–Ottawa Scale (NOS) was used to assess quality of cohort studies. This scale assesses sample representativeness, comparability between patients with and without NODID RSIE, quality of outcome assessment, and adequacy of follow-up (full scoring details in Supplementary Appendix A1). Risk of bias was deemed high if a study scored 0–3, moderate if a study scored 4–6, and low if a study scored 7–9.

Primary endpoint of the meta-analytic study was mortality secondary to RSIE during hospitalization, regardless of treatment. Secondary endpoint was in-hospital open-heart surgery related to IE.

Statistical analysis and data synthesis. SPSS version 17.0 software (IBM Inc., New York, New York) and Review Manager 5.3 software and STATA version 11.2 (StataCorp, College Station, Texas) were used for statistical computations. Descriptive data are presented as mean ± SD, medians (interquartile range), or proportions, depending on variable distribution. For continuous variables, deviations from normality were determined with the Kolmogorov–Smirnov test. For categorical variables, significant differences between groups were assessed with chi-square or Fisher exact tests. Differences among groups for continuous parameters were assessed by Student’s t test or analysis of variance with Bonferroni correction for multiple comparisons if normally distributed, and Mann–Whitney U or Kruskal–Wallis tests if not normally distributed. A p-value of < 0.05 was considered significant. Univariable logistic regression was performed to identify determinants of endocarditis-related events. Factors significant at the p < 0.10 level in the univariate analyses were included in multivariable logistic regression analysis. Indicators with a 95% confidence interval for the odds ratio (OR) not including 1 were considered significant.

Meta-analyses were conducted to compare prognoses between NODID and non-NODIDRSIE cases for primary and secondary endpoints. Prognosis was measured with relative risks (RR) with 95% confidence intervals (CI). Pooled RR was computed for primary and secondary endpoints with the DerSimonian-Laird method in a random effects model. Heterogeneity among studies was assessed qualitatively and quantitatively (using chi-square test of heterogeneity and I2 statistic).

Results

Baseline characteristics of study population. In a cohort of 300 IE patients, 57 patients (19%) were diagnosed with RSIE: 22 NODID (39%) and 35 non-NODID (61%) cases, including 11 non-NODID cases (19%) with IVDU and 24 (42%) with cardiac devices (Fig. 1). Baseline characteristics of NODID and non-NODIDRSIE cases are detailed in Table 1.

Compared to non-NODID RSIE patients, NODID RSIE cases included a significantly higher percentage of intravascular catheter carriers (23% vs 3%; p = 0.027) and congenital heart disease baseline (18% vs 0%; p = 0.019). Etiology for NODID RSIE was mainly polymicrobial, while non-NODIDRSIE cases presented Staphylococcus aureus as the main etiopathogen (63%) compared to NODID RSIE cases (27%; p = 0.009). NODID and non-NODIDRSIE groups did not differ in clinical presentation and echocardiogram findings (Table 1).

Clinical prognosis by RSIE subgroup. Of the 57 RSIE cases, 6 patients (11%) died during hospitalization, all secondary to IE, and 5 of these patients (83%) had NODID RSIE. Furthermore, 5 of the 57 RSIE patients (9%) required open-heart surgery: 2 patients had tricuspid valve replacement, 2 patients had tricuspid valve repair with vegetation removal, and 1 case had vegetation removal and ventricular septal defect repair. Of those 5 patients, 4 (80%) had NODID RSIE and 1 (20%) was associated with IVDU. No patients who underwent open-heart surgery died during hospital admission. Mean hospital stay was: 24.7 ± 20.0 days (range: 2–122 days; median: 23 days; quartiles 1–3: 11–32 days). NODID RSIE patients had worse prognosis than non-NODID cases, based on rate of adverse endocarditis-related events during hospitalization (41% vs 6%; p = 0.001) and in-hospital mortality (23% vs 3%; p = 0.027) (Table 2). Additionally, NODID RSIE cases had higher rate of open-heart surgery than non-NODID cases (18% vs 3%; p = 0.067).

Fifty-one patients were discharged after treatment. Follow-up ranged 1–127 months (mean: 49 ± 41 months; median: 35 months; quartiles 1–3: 12–83 months). Of these 51 patients, 13 patients (25%) died during follow-up: 12 from non-RSIE endocarditis complications (2 from neoplasia, 2 from respiratory infection, 4 from multiorgan failure due to sepsis, 2 from left-sided heart failure decompensation, 1 from acute renal failure, and 1 from complicated femur fracture), and 1 from right-sided heart failure decompensation with chronic right ventricle dysfunction (this patient had NODID RSIE). No differences were found during follow-up in mortality or morbidity between NODID non-NODID RSIE cases (Table 2). No patients required open-heart surgery during follow-up, and only 1 non-NODID RSIE patient presented relapse.

In the subgroup analysis dividing the non-NODID group in IVDU and cardiac devices carriers the results during hospitalization and follow-up were similar than between NODID and non-NODID groups, with the exception of pulmonary and paradoxical systemic embolisms, which were more frequent in the IVDU group (Supplementary Table A2). The subanalysis evaluating NODID group separately (congenital heart disease patients with intravascular catheter carriers vs patients without these features) showed that these subgroups presented worse prognosis than RSIE associated with cardiac devices but the worse prognosis for congenital heart disease group was secondary to high risk of interventions (50% of cases; Supplementary Table A3).
| Variable (n = 57)                  | Non-NODID RSIE (n = 35) | NODIDRSIE (n = 22) | p     |
|----------------------------------|-------------------------|--------------------|-------|
| Gender [males; n (%)]            | 24 (69)                 | 15 (68)            | 0.975 |
| Age (years; mean ± SD)           | 60.3±19.7               | 56.7±18.9          | 0.500 |

**COMORBIDITIES**

| Variable                          | Non-NODID RSIE (n = 35) | NODIDRSIE (n = 22) | p     |
|-----------------------------------|-------------------------|--------------------|-------|
| Hypertension, n (%)               | 17 (49)                 | 8 (36)             | 0.366 |
| Dyslipidemia (%)                  | 13 (37)                 | 6 (27)             | 0.422 |
| Diabetes mellitus, n (%)          | 9 (26)                  | 6 (27)             | 0.897 |
| HIV, n (%)                        | 5 (14)                  | 0 (0)              | 0.145 |
| Hemodialysis, n (%)               | 1 (3)                   | 3 (14)             | 0.288 |
| Cancer, n (%)                     | 2 (6)                   | 4 (18)             | 0.192 |
| Intravascular catheter, n (%)     | 1 (3)                   | 5 (23)             | 0.027 |
| Coronary heart disease, n (%)     | 8 (23)                  | 4 (18)             | 0.750 |
| Left-side prosthetic or repaired valve, n (%) | 1 (3) | 3 (14) | 0.288 |
| Right-side prosthetic or repaired valve, n (%) | 1 (3) | 1 (5) | >0.999 |
| Congenital heart disease, n (%)   | 0 (0)                   | 4 (18)             | 0.019 |
| Charlson score (mean ± SD)        | 2.0 ± 1.6               | 2.3 ± 1.6          | 0.536 |

**MICROBIOLOGY**

| Variable                          | Non-NODID RSIE (n = 35) | NODIDRSIE (n = 22) | p     |
|-----------------------------------|-------------------------|--------------------|-------|
| *Staphylococcus aureus*, n (%)    | 22 (63)                 | 6 (27)             | 0.009 |
| *Staphylococcus epidermidis*, n (%) | 3 (9)           | 2 (9)             | >0.999 |
| *Enterococcus faecalis*, n (%)    | 2 (6)                   | 1 (5)              | >0.999 |
| *Streptococcus viridans*, n (%)   | 0 (0)                   | 2 (9)              | 0.145 |
| *Streptococcus bovis/gallolyticus*, n (%) | 1 (3) | 1 (5) | >0.999 |
| *Escherichia coli*, n (%)         | 1 (3)                   | 0 (0)              | >0.999 |
| *Pseudomonas aeruginosa*, n (%)   | 0 (0)                   | 1 (5)              | 0.386 |
| *Staphylococcus capitis*, n (%)   | 0 (0)                   | 1 (5)              | 0.386 |
| *Streptococcus mitis*, n (%)      | 0 (0)                   | 1 (5)              | 0.386 |
| Other microorganisms, n (%)       | 5 (14)                  | 4 (18)             | 0.722 |
| Multiple microorganisms, n (%)    | 0 (0)                   | 2 (9)              | 0.145 |
| Negative, n (%)                   | 1 (3)                   | 1 (5)              | >0.999 |

**CLINICAL PRESENTATION**

| Variable                          | Non-NODID RSIE (n = 35) | NODIDRSIE (n = 22) | p     |
|-----------------------------------|-------------------------|--------------------|-------|
| Fever, n (%)                      | 33 (94)                 | 21 (96)            | >0.999 |
| Dyspnea, n (%)                    | 5 (14)                  | 7 (32)             | 0.114 |
| Hemoglobin (mg/dL), median (IQR)  | 11.1 (3.2)              | 10.7 (2.4)         | 0.142 |
| Hematocrit, mean ± SD             | 34.2 ± 7.3              | 32.6 ± 4.5         | 0.383 |
| Leucocytes (10^6/L), mean ± SD    | 11527 ± 6531            | 12460 ± 6828       | 0.608 |
| CRP (mg/dL), mean ± SD            | 10.2 ± 7.9              | 12.8 ± 11.1        | 0.311 |
| Creatinine (mg/dL), median (IQR)  | 0.8 (0.62)              | 1.0 (0.82)         | 0.456 |
| Protein (mg/dL), mean ± SD        | 6.3 ± 1.2               | 6.2 ± 1.0          | 0.701 |
| Albumin (mg/dL), mean ± SD        | 3.4 ± 0.9               | 3.4 ± 0.8          | 0.869 |
| Prealbumin (mg/dL), mean ± SD     | 20.9 ± 7.6              | 19.8 ± 6.8         | 0.577 |
| Nutritional status (malnourished), n(%) | 14 (40) | 10 (46) | 0.685 |
| Kinds of antibiotics used per patient, median (IQR) | 2 (1) | 2 (1) | 0.748 |

**ECHOCARDIOGRAPHIC FINDINGS AT DIAGNOSIS**

| Variable                          | Non-NODID RSIE (n = 35) | NODIDRSIE (n = 22) | p     |
|-----------------------------------|-------------------------|--------------------|-------|
| Location of major vegetation, n (%) | 10 (91) | 13 (59) | 0.123 |
| Pulmonary valve                    | 0 (0)                   | 6 (27)             |       |
| Other locations                    | 1 (9)                   | 3 (14)             |       |
| Morphological complication, n (%)  | 34 (97)                 | 19 (86)            | 0.288 |
| No                                | 1 (3)                   | 3 (14)             |       |
| Yes                               | 15.5 ± 8.5              | 18.4 ± 10.7        | 0.279 |
| LV EF (%), median (IQR)           | 58.0 (10.0)             | 58.5 (10.5)        | 0.948 |
| TAPSE (mm), mean ± SD             | 20.3 ± 3.7              | 20.6 ± 3.4         | 0.777 |
| FAC (%), median (IQR)             | 44.7 (10.0)             | 43.1 (7.3)         | 0.470 |
| Significant TR (≥ 3), n (%)       | 0.614                   |                   |       |

Continued...
predictors of adverse endocarditis-related events for RSie.

Endocarditis-related event rate (in-hospital mortality or open-heart surgery during IE event) was significantly higher in patients with C-reactive protein (CRP) levels >16 mg/dL (45% vs 13%; \( p = 0.022 \)), patients undergoing hemodialysis (27% vs 2%; \( p = 0.020 \)) and patients with Charlson score >3 (45% vs 17%; \( p = 0.056 \)). Neither Staphylococcus aureus (14% vs 24%; \( p = 0.346 \)) nor polymicrobial infections (50% vs 18%; \( p = 0.352 \)) were significantly associated with endocarditis-related event rate in our series. NODID RSIE cases were related to adverse events: 41% (9 of 22 cases) died (\( n = 5 \)) or required open-heart surgery (\( n = 4 \)) during hospitalization (\( p = 0.004 \)). Only NODID RSIE cases (OR = 19.29; 95%CI: 2.23–167.16; \( p = 0.007 \)) and those with Charlson score >3 (OR = 9.75; 95%CI: 1.30–73.17; \( p = 0.027 \)) were associated with endocarditis complications during hospitalization. A nonsignificant trend for endocarditis-related events was also observed in patients with CRP >16 mg/dL (OR = 7.35; 95%CI: 0.78–69.40; \( p = 0.082 \)).

Meta-analysis of RSIE clinical prognosis. Our initial search identified 573 publications. After screening titles and abstracts, 18 publications were selected for full-text review; of these, 15 did not meet inclusion criteria (Fig. 2). Therefore, we combined 3 published studies \(^{10,11,13}\) with our results (1 longitudinal prospective and 3 longitudinal retrospective cohorts) for a meta-analysis involving a total of 320 individuals with RSIE.

Estimated NODID RSIE incidence for the 4 studies was 30% (96 of 320 individuals; range: 17%–68%), with in-hospital mortality of 26% (25 of 96 individuals; range: 23%–30%). Main characteristics of each study cohort are reported in Supplementary Table A4. Risk of bias among the included studies was low (mean NOS score: 8 of 9; Supplementary Table A5). Endocarditis-related mortality during hospitalization occurred in 45 patients (14%). Open-heart surgery could only be assessed in 2 studies, which indicated an incidence of 8% (15 of 178 individuals). NODID RSIE cases presented higher in-hospital mortality (RR = 2.81; 95%CI: 1.61–4.90; \( p < 0.001 \)).

### Table 1. Demographic, clinical, microbiological, and imaging characteristics of NODID and non-NODID right-sided infective endocarditis (RSIE) cases. \(^{a}\)Excluding RSIE with intracardiac devices. \(^{b}\)Including perforation, fistulae, and abscess. HIV = human immunodeficiency virus; CRP = C-reactive protein; LVEF = left ventricular ejection fraction; TAPSE = tricuspid annular plane systolic excursion; FAC = fractional area change; TR = tricuspid regurgitation; PR = pulmonary regurgitation; IQR = interquartile range.

| Variable (n = 57) | Non-NODID RSIE (n = 35) | NODID RSIE (n = 22) | \( p \) |
|-------------------|--------------------------|---------------------|------|
| No                | 23 (66)                  | 13 (59)             |      |
| Yes               | 12 (34)                  | 9 (41)              |      |
| Significant PR (\( \geq 3 \), n (%)) |                         |                     |      |
| No                | 35 (100)                 | 19 (86)             | 0.053|
| Yes               | 0 (0)                    | 3 (14)              |      |

### Table 2. Clinical complications of patients with NODID or non-NODID right-sided infective endocarditis (RSIE) during hospitalization and after discharge. Values are n (%). IVDU = Intravenous drug users; RSIE: right-sided infective endocarditis.

| Variable | Non-NODID RSIE (n = 35) | NODID RSIE (n = 22) | \( p \) |
|----------|--------------------------|---------------------|------|
| In-hospital mortality and/or open-heart surgery | 2 (6) | 9 (41) | 0.001 |
| In-hospital mortality | 1 (3) | 5 (23) | 0.027 |
| Open-heart surgery | 1 (3) | 4 (18) | 0.067 |
| Pulmonary embolism | 17 (49) | 11 (50) | 0.916 |
| Systemic embolism | 3 (9) | 0 (0) | 0.276 |

| Variable | Non-NODID RSIE (n = 35) | NODID RSIE (n = 22) | \( p \) |
|----------|--------------------------|---------------------|------|
| Mortality for any cause of death | 7 (21) | 6 (35) | 0.256 |
| Mortality for oncologic pathologies | 0 (0) | 2 (12) | 0.107 |
| Mortality for respiratory pathologies | 1 (3) | 1 (6) | >0.999 |
| Mortality for cardiac pathologies | 1 (3) | 2 (12) | 0.255 |
| Mortality for right heart failure | 0 (0) | 1 (6) | 0.333 |
| Mortality for other causes | 5 (15) | 1 (6) | 0.650 |
| Relapse | 1 (3) | 0 (0) | >0.999 |
I² = 0.0%; Fig. 3A) and higher necessity of open-heart surgery (RR = 13.89; 95%CI: 4.14–46.60; p < 0.001; I² = 0.0%; Fig. 3B) than non-NODID RSIE cases.

**Discussion**

This study demonstrates that NODID RSIE, without association to IVDU or cardiac devices, has the worst clinical prognosis among RSIE with in-hospital mortality of >20%. This poor prognosis was also observed in meta-analysis of published literature, and NODIDRSIE patients had a higher rate of open-heart surgery than other RSIE cases. Additionally, predisposing factors for NODID RSIE also differ, as intravascular catheters and congenital heart disease were more frequent in these cases.

**Incidence and predisposing factors for NODID RSIE.** Incidence of RSIE has been described as 5%–10% of IE. However, recently published studies indicate an increased incidence of 10%–20%. Our study found a similarly increased incidence of 19%. These changes may reflect growing predisposing risk factors for RSIE, especially for NODID cases.

Developed countries have recently experienced an increased population with comorbidities that require more invasive explorations and venous access, as carriers of intravascular catheters particularly affect RSIE incidence. Georges et al. reported intravascular catheters a portal entry for RSIE in 27% of cases from an intensive care unit cohort. Furthermore, Chrissoheris et al. reported right heart cavities are affected in 67% of cases with IE attributed to intravascular catheters. In addition, congenital heart disease in adults, usually associated with RSIE, is currently more prevalent than it was 10 years ago due to improved treatments, especially in children. Ruotsalainen et al. reported five-times greater risk of Staphylococcus aureus IE in patients with bacteremia and congenital heart disease than in those without these conditions.
Other factors such as hemodialysis treatment or previous cancer seem to be risks for NODID RSIE\(^3,11,21\), although there is a tendency, in our study these associations were not significant. A subanalysis by Ortiz et al.\(^11\) described a significant association of NODID RSIE with cancer and chronic renal failure. Further, Ludvigsen et al.\(^24\) reported IE incidence is 38-times higher for hemodialysis patients than untreated patients. These epidemiological changes could explain not only the increase in numbers, but also the increase in RSIE cases compared to LSIE in our IE population, especially for NODID RSIE cases\(^11,14,20\). In a nutshell, patients on hemodialysis, congenital heart disease, with polymicrobial infections or malignancy have a higher mortality rate when being treated for RSIE.

Prognosis of RSIE. Mortality of RSIE patients has been mainly analyzed based on IVDU and cardiac device use\(^1\). In our study, NODID RSIE carried a high risk of endocarditis-related complications, with in-hospital mortality similar to LSIE, which is ~20%–30%\(^25\). This higher mortality was also confirmed in our meta-analysis, showing global worse prognosis of RSIE patients. This group also had a higher rate of open-heart surgery than NODID RSIE cases, although those who underwent surgery did not have a worse prognosis and were all discharged after their intervention. Other studies have demonstrated good results for open-heart surgery on isolated RSIE, with in-hospital mortality of <6%\(^26\). Nevertheless, open-heart surgery rates for LSIE, usually between ~35%–60%, are significantly higher than for RSIE, even for NODID RSIE with similar complexity scores\(^5,25\).

Further, Charlson score also was a strong independent factor for RSIE-related complications, highlighting a high risk of complications for NODID RSIE cases with Charlson score >3. In addition, CRP is a laboratory risk-marker that is well-studied in IE\(^27,28\). Our univariate analysis demonstrated a relationship between CRP > 16 mg/dL and endocarditis complications. However, it is well-known as an unspecific biomarker and further studies are needed to confirm CRP as a possible tool for making treatment decisions.

Ramos-Martínez et al.\(^29\) demonstrated significantly higher in-hospital mortality for patients undergoing hemodialysis compared to untreated patients. Although the cohort included RSIE and LSIE, our results are concordant with these data and indicate that patients with RSIE and undergoing hemodialysis could have a worse prognosis.

Clinical implications of pure RSIE. NODID RSIE is a group with a poor prognosis, similar to LSIE. Therefore, our results break the good-prognosis paradigm that has been described for RSIE and should alter how NODID RSIE is prevented and treated. Based on our findings, we may hypothesize that demographic, clinical, microbiological and imaging characteristics in NODID versus non-NODID cases may differ and therefore the response to a similar treatment is also different (Fig. 4). Preventive programs in high-risk groups, including intravascular catheter carriers, chronic hemodialysis patients, or cases with congenital heart disease, should be updated to decrease the potential number of new RSIE cases. Further, high in-hospital mortality of these patients may change the treatment decision-making scheme classically accepted for RSIE. Invasive treatment guidelines and expert consensus of IE are usually wider for LSIE than RSIE\(^1,2,5\). However, as our results and other studies show, in-hospital surgery has good results in RSIE mortality rate\(^26,30\). For this reason, indications of open-heart surgery in RSIE should be reviewed, especially in cases of NODID RSIE with other markers of complicated course, such as Charlson index >3, because of the high risk of in-hospital mortality for these patients.
As in LSIE, early surgery in high-risk cases without contraindications could improve therapeutic results in those patients. Furthermore, a new percutaneous approach proposed for tricuspid vegetation removal in high-risk surgical cases has shown good results; this may provide another therapeutic solution for patients with NODID RSIE. Nevertheless, further studies are required to confirm our data.

**Study limitations.** We are aware of several limitations of our work. First, the retrospective study design and unincentric data source used affects to underestimation of the true number of IE cases. Second, selection bias inherent to the tertiary hospital with cardiac surgery department also affects the number of IE. Third, although our study showed that NODID RSIE is associated with in-hospital endocarditis-related events and mortality, statistical analysis does not include all possible influential prognosis variables. Nonetheless, we were able to analyze more than 20 of these variables that demonstrate our findings. Furthermore, our meta-analysis based on only four longitudinal studies and three of them are retrospective, so the results are limited. Nevertheless, this analysis is the largest series evaluating NODID RSIE prognosis and thus provides information on the global tendency of this group in the past 10 years. Larger studies are required to identify possible therapeutic option to decrease mortality of these patients. All these limitations should be taken into account when interpreting our results.

**Conclusions**

Our study suggests that NODID RSIE, not associated with cardiac devices or IVDU, has a poor in-hospital prognosis and higher necessity for open-heart surgery than other RSIE groups. Additionally, predisposing factors such as intravascular catheters or congenital heart disease should be evaluated as risk factors to identify new approaches to prevent NODID RSIE.

Received: 11 December 2019; Accepted: 7 April 2020; Published online: 28 April 2020

**References**

1. Habib, G. et al. ESC Guidelines for the management of infective endocarditis. European Heart Journal 36 (2015).
2. Baddour, L. M. et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications. Circulation 132, 1435–1486 (2015).
3. Yuan, S. M. Right-sided infective endocarditis: Recent epidemiologic changes. Int. J. Clin. Exp. Med. 7, 199–218 (2014).
4. Olmos, C. et al. The Evolving Nature of Infective Endocarditis in Spain: A Population-Based Study (2003 to 2014). J. Am. Coll. Cardiol. 70, 2795–2804 (2017).
5. Cahal, T. J. et al. Challenges in Infective Endocarditis. J. Am. Coll. Cardiol. 69, 325–44 (2017).
6. Greenspan, A. J. et al. 16-Year Trends in the Infection Burden for Pacemakers and Implantable Cardioverter-Defibrillators in the United States 1993 to 2008. J. Am. Coll. Cardiol. 58, 1001–6 (2011).
7. Dienerker, I. et al. Predictors of long-term survival free from relapses after extraction of infected CIED. Europace 20, 1018–1027 (2018).
8. Stav, V. et al. Comparison of Clinical Characteristics and Prognosis in Patients with Right- and Left-sided Infective Endocarditis. Rambam Haimonides Med. J. 1, 1–8. https://doi.org/10.5041/RMMJ.10338 (2018).
9. Revilla, A. et al. Endocarditis derecha aislada en pacientes no adictos a drogas por vía parenteral. Rev. Española Cardiol. 61, 1253–1259 (2008).
10. Mi, M. Y., Nelson, S. B. & Weiner, B. Clinical and Echocardiographic Factors Associated With In-Hospital Mortality in Patients With Infective Endocarditis Affecting the Native Tricuspid Valve. Am. J. Cardiol. 1–12. https://doi.org/10.1016/j.amjcard.2016.06.011 (2016).
11. Ortiz, C. et al. Clinical classification and prognosis of isolated right-sided infective endocarditis. Medicine (Baltimore). 93, 1–6 (2014).
12. Raut, N., Potdar, A. & Sharma, S. Tricuspid valve endocarditis in non-drug abusers: A case series from India. Indian Heart J. 70, 476–481 (2018).
13. Georges, H. et al. Outcome and prognostic factors of patients with right-sided infective endocarditis requiring intensive care unit admission. BMC Infect. Dis. 18, 1–8 (2018).
14. Galal, H., Rifaei, O., Rahman, M. A. & El-sayed, H. Prevalence and characteristics of tricuspid valve endocarditis among patients presented to Ain Shams Hospital echocardiography lab; one year study. Egyptian Heart J. 18, 1–12. https://doi.org/10.1016/j.eghj.2017.12.009 (2018).
15. Li, J. S. et al. Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis. Clin. Infect. Dis. 30, 633–638 (2000).
16. Kasier, M. et al. VALIDATION OF THE MINI NUTRITIONAL ASSESSMENT SHORT-FORM (MNA® -SF): A PRACTICAL TOOL FOR IDENTIFICATION OF NUTRITIONAL STATUS. J. Nutr. Heal. Aging 13, 782–788 (2009).
17. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & Group, P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339, 332–336 (2009).
18. Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25, 603–605 (2010).
19. D’Souza, R. et al. Anticoagulation for pregnant women with mechanical heart valves: a systematic review and meta-analysis. Eur. Heart J. 38, 1509–1516 (2017).
20. Lee, M. et al. Clinical Features of Right-Sided Infective Endocarditis Occurring in Non-Drug Users. J Korean Med Sci 29, 776–781 (2014).
21. Chriassheris, M. P. et al. Endocarditis Complicating Central Venous Catheter Bloodstream Infections: A Unique Form of Health Care Associated Endocarditis. Clin. Cardiol. 32, 48–54 (2009).
22. Baumgartner, H. et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010) The Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC). Eur. Heart J. 31, 2915–2957 (2010).
23. Ruotsalainen, E. et al. Clinical manifestations and outcome in Staphylococcus aureus endocarditis among injection drug users and nonaddicts: a prospective study of 74 patients. BMC Infect. Dis. 6, 1–10 (2006).
24. Ludvigsen, L. U. & et al. Infective endocarditis in patients receiving chronic hemodialysis: A 21-year observational cohort study in Denmark. Am. Heart J. https://doi.org/10.1016/j.ahj.2016.08.012 (2016).
25. Chu, V. H. et al. The Association Between Surgical Indications, Operative Risk and Clinical Outcome in Infective Endocarditis: A Prospective Study From the International Collaboration on Endocarditis. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.114.012461 (2014).
26. Witten, J. C. et al. Surgical treatment of right-sided infective endocarditis. *J. Thorac. Cardiovasc. Surg.* 1–10. https://doi.org/10.1016/j.jtcs.2018.07.112 (2018).
27. Ris, T. et al. Inflammatory Biomarkers in Infective Endocarditis: Machine Learning to Predict Mortality. *Clin Exp Immunol.* 1–13. https://doi.org/10.1111/cei.13266 (2019).
28. Mohanan, S. et al. Baseline C-reactive protein levels and prognosis in patients with infective endocarditis: A prospective cohort study. *Indian Heart J.* 1–7. https://doi.org/10.1016/j.ihj.2018.05.001 (2018).
29. Ramos-Martinez, A. et al. Prognostic factors of Infective Endocarditis in Patients on Hemodialysis: A Case Series from a National Multicenter Registry. *Int. J. Cardiol.* 1–46. https://doi.org/10.1016/j.ijcard.2017.04.086 (2017).
30. Jiang, S. et al. Surgical treatment of isolated right-sided infective endocarditis. *Texas Hear. Inst. J.* 38, 639–642 (2011).
31. George, B., Voelkel, A., Kotter, J., Leventhal, A. & Gurley, J. A Novel Approach to Percutaneous Removal of Large Tricuspid Valve Vegetations Using Suction Filtration and Veno-Venous Bypass: A Single Center Experience. *Catheter. Cardiovasc. Interv.* 60, 1–7 (2017).

**Author contributions**
P.V. and S.M. wrote the main manuscript text; M.M., J.M.F., X.A. and R.R. helped supervise the cardiac imaging analysis; D.B. contributed in clinical data analysis. M.R. contributed in statistical data analysis. J.A. and R.B. provided critical revision of the article; E.B. prepared the figures. All authors reviewed the manuscript.

**Competing interests**
The authors declare no competing interests.

**Additional information**
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-64220-z.

**Correspondence** and requests for materials should be addressed to S.M.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020